NCTN: A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD (AAML1031)
Getting access
No access information recorded yet.
About this database
| Last updated | 2026-08-25 |
|---|